首页 > 最新文献

Neurodegenerative disease management最新文献

英文 中文
Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies. 神经丝蛋白轻链:处于基因导向疗法清晰与混乱交叉点的生物标志物。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-11-15 DOI: 10.1080/17582024.2024.2421738
Michael Christian A Virata, Jesus Alfonso Catahay, Giuseppe Lippi, Brandon M Henry

Neurofilament light chain (NfL) is a promising biomarker for neurodegenerative diseases, measurable in both CSF and blood upon neuroaxonal damage. While CSF analysis was traditionally used, blood-based assays now offer a less invasive alternative. NfL levels correlate with disease severity and progression in conditions like Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis and Huntington's disease. Clinical trials demonstrate its utility as a pharmacodynamic biomarker in MS and ALS. The FDA's approval of Tofersen for SOD1-ALS based on NfL reduction underscores its growing acceptance as surrogate marker. However, challenges remain in standardizing assays, interpreting clinical correlations, low specificity and understanding the dynamics between CSF and blood NfL levels. Addressing these issues is crucial for maximizing NfL's potential in neurodegenerative disease management.

神经丝蛋白轻链(NfL)是一种很有前景的神经退行性疾病生物标记物,在神经轴受损时可在脑脊液和血液中检测到。传统上使用脑脊液分析,而现在基于血液的检测提供了一种侵入性较小的替代方法。NfL 水平与阿尔茨海默病、肌萎缩侧索硬化症、多发性硬化症和亨廷顿氏病等疾病的严重程度和进展相关。临床试验证明,它可以作为多发性硬化症和渐冻症的药效生物标记物。美国食品及药物管理局批准 Tofersen 用于 SOD1-ALS 的治疗,其依据是 NfL 的降低,这表明它作为替代标志物的认可度在不断提高。然而,标准化检测、解释临床相关性、低特异性以及了解脑脊液和血液 NfL 水平之间的动态变化等方面仍存在挑战。解决这些问题对于最大限度地发挥 NfL 在神经退行性疾病管理中的潜力至关重要。
{"title":"Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.","authors":"Michael Christian A Virata, Jesus Alfonso Catahay, Giuseppe Lippi, Brandon M Henry","doi":"10.1080/17582024.2024.2421738","DOIUrl":"https://doi.org/10.1080/17582024.2024.2421738","url":null,"abstract":"<p><p>Neurofilament light chain (NfL) is a promising biomarker for neurodegenerative diseases, measurable in both CSF and blood upon neuroaxonal damage. While CSF analysis was traditionally used, blood-based assays now offer a less invasive alternative. NfL levels correlate with disease severity and progression in conditions like Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis and Huntington's disease. Clinical trials demonstrate its utility as a pharmacodynamic biomarker in MS and ALS. The FDA's approval of Tofersen for SOD1-ALS based on NfL reduction underscores its growing acceptance as surrogate marker. However, challenges remain in standardizing assays, interpreting clinical correlations, low specificity and understanding the dynamics between CSF and blood NfL levels. Addressing these issues is crucial for maximizing NfL's potential in neurodegenerative disease management.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-13"},"PeriodicalIF":2.3,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An interdisciplinary approach to rehabilitation in Parkinson's disease: case series. 帕金森病康复的跨学科方法:病例系列。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-11-14 DOI: 10.1080/17582024.2024.2421736
Emilie R Lowell, Chelsea Macpherson, Katya Villarreal-Cavazos, Anuja Chandrana, Jordanna S Sevitz, Kelly Veit, Avery Dakin, Lori Quinn, Michelle S Troche

Interdisciplinary care is increasingly promoted to enhance satisfaction and outcomes for individuals with complex medical conditions, such as Parkinson's disease (PD). However, there is little research on the feasibility or efficacy of interdisciplinary care in clinical settings. And, while the use of an integrated team of allied health professionals has the potential to provide significant health benefits to individuals with PD, there are educational and logistical barriers to the use of interdisciplinary care in clinical settings. An interdisciplinary care model was described that aimed to facilitate these benefits and alleviate some of these known clinical feasibility challenges. Three cases are also provided to exemplify how this approach to collaborative care was used to address individual needs and to highlight some of the successes and challenges associated with the implementation of an interdisciplinary and person-centered care model via telehealth. These cases may help clinicians adopt techniques to facilitate greater collaboration across disciplines or aid in the development of a feasible interdisciplinary program in their own clinics. Further research is needed to further enhance individual outcomes and integrate other disciplines into the care team.

为了提高帕金森病(PD)等复杂病症患者的满意度和治疗效果,跨学科护理得到了越来越多的推广。然而,有关跨学科护理在临床环境中的可行性或有效性的研究却很少。而且,虽然使用由专职医疗人员组成的综合团队有可能为帕金森病患者带来显著的健康益处,但在临床环境中使用跨学科护理还存在教育和后勤方面的障碍。本文介绍了一种跨学科护理模式,旨在促进这些益处的实现,并缓解一些已知的临床可行性挑战。此外,还提供了三个案例来说明如何使用这种协作护理方法来满足个人需求,并强调了通过远程医疗实施跨学科和以人为本的护理模式所取得的一些成功和面临的挑战。这些案例可能有助于临床医生采用促进跨学科协作的技术,或帮助他们在自己的诊所制定可行的跨学科计划。要进一步提高个人疗效并将其他学科整合到护理团队中,还需要进一步的研究。
{"title":"An interdisciplinary approach to rehabilitation in Parkinson's disease: case series.","authors":"Emilie R Lowell, Chelsea Macpherson, Katya Villarreal-Cavazos, Anuja Chandrana, Jordanna S Sevitz, Kelly Veit, Avery Dakin, Lori Quinn, Michelle S Troche","doi":"10.1080/17582024.2024.2421736","DOIUrl":"https://doi.org/10.1080/17582024.2024.2421736","url":null,"abstract":"<p><p>Interdisciplinary care is increasingly promoted to enhance satisfaction and outcomes for individuals with complex medical conditions, such as Parkinson's disease (PD). However, there is little research on the feasibility or efficacy of interdisciplinary care in clinical settings. And, while the use of an integrated team of allied health professionals has the potential to provide significant health benefits to individuals with PD, there are educational and logistical barriers to the use of interdisciplinary care in clinical settings. An interdisciplinary care model was described that aimed to facilitate these benefits and alleviate some of these known clinical feasibility challenges. Three cases are also provided to exemplify how this approach to collaborative care was used to address individual needs and to highlight some of the successes and challenges associated with the implementation of an interdisciplinary and person-centered care model via telehealth. These cases may help clinicians adopt techniques to facilitate greater collaboration across disciplines or aid in the development of a feasible interdisciplinary program in their own clinics. Further research is needed to further enhance individual outcomes and integrate other disciplines into the care team.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication. 测量多发性硬化症患者的疲劳程度--应使用哪种问卷?通俗易懂的出版物摘要。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-02-01 Epub Date: 2024-03-19 DOI: 10.2217/nmt-2023-0034
Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann

What is this summary about?: This summary explains the findings of a recent study that compared different questionnaires used by doctors to measure levels of fatigue in people with multiple sclerosis (MS). The aim of the study was to find out which questionnaire doctors should use to measure fatigue in people with MS in the future. Fatigue, which can be described as the overwhelming feeling of tiredness or exhaustion, is a very common symptom of MS. For the majority of people with MS, fatigue is one of the worst symptoms of MS, so it is essential that doctors can measure it accurately. Currently, people with MS are asked to complete questionnaires so that their care team can see the effect of fatigue on their day-to-day lives. There are many questionnaires that are used to measure fatigue in people with MS. It would be valuable to come to an agreement, based on evidence from research like this study, on which questionnaire is the most appropriate for measuring fatigue in both research and healthcare settings. This study compared a questionnaire called the PROMIS® Fatigue (MS) 8a, referred to throughout this summary as the PROMIS® MS Fatigue Short Form, with two of the most commonly used questionnaires: the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS). The questionnaires were compared to see which one should be recommended to doctors for measuring fatigue in people with MS.

What are the key takeaways?: It was found that while all three questionnaires were good, the PROMIS® MS Fatigue Short Form questionnaire was better than the other two questionnaires at showing differences in levels of fatigue between people with MS. The PROMIS® MS Fatigue Short Form was also found to be better than the Fatigue Severity Scale (FSS) at showing changes in the person with MS's level of fatigue. The PROMIS® MS Fatigue Short Form questionnaire may help people with MS to better communicate challenges with their fatigue to their doctors.

What was the main conclusion reported by the researchers?: The study suggests that the PROMIS® MS Fatigue Short Form questionnaire is a helpful tool for doctors and people with MS to measure fatigue.

本摘要说明了近期一项研究的结果,该研究比较了医生用于测量多发性硬化症(MS)患者疲劳程度的不同问卷。这项研究的目的是找出医生今后应该使用哪种问卷来测量多发性硬化症患者的疲劳程度。疲劳可以被描述为一种难以承受的疲倦或精疲力竭的感觉,是多发性硬化症的一种非常常见的症状。对于大多数多发性硬化症患者来说,疲劳是多发性硬化症最严重的症状之一,因此医生必须对其进行准确测量。目前,多发性硬化症患者需要填写调查问卷,以便护理团队了解疲劳对其日常生活的影响。用于测量多发性硬化症患者疲劳程度的问卷有很多。根据本研究等研究的证据,就哪种问卷最适合在研究和医疗环境中测量疲劳达成一致是非常有价值的。本研究将 PROMIS® 疲劳(MS)8a(在本摘要中称为 PROMIS® MS 疲劳简表)问卷与两种最常用的问卷:疲劳严重程度量表(FSS)和改良疲劳影响量表(MFIS)进行了比较。对这两种问卷进行了比较,以确定应向医生推荐哪一种问卷来测量多发性硬化症患者的疲劳程度:研究发现,虽然这三种问卷都不错,但在显示多发性硬化症患者疲劳程度差异方面,PROMIS® 多发性硬化症疲劳简表问卷优于其他两种问卷。在显示多发性硬化症患者疲劳程度的变化方面,PROMIS® 多发性硬化症疲劳简表也优于疲劳严重程度量表(FSS)。PROMIS®多发性硬化症疲劳简表问卷可以帮助多发性硬化症患者更好地向医生表达他们在疲劳方面遇到的挑战:研究表明,PROMIS® 多发性硬化症疲劳简表问卷是医生和多发性硬化症患者测量疲劳的有效工具。
{"title":"Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication.","authors":"Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann","doi":"10.2217/nmt-2023-0034","DOIUrl":"10.2217/nmt-2023-0034","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary explains the findings of a recent study that compared different questionnaires used by doctors to measure levels of fatigue in people with multiple sclerosis (MS). The aim of the study was to find out which questionnaire doctors should use to measure fatigue in people with MS in the future. Fatigue, which can be described as the overwhelming feeling of tiredness or exhaustion, is a very common symptom of MS. For the majority of people with MS, fatigue is one of the worst symptoms of MS, so it is essential that doctors can measure it accurately. Currently, people with MS are asked to complete questionnaires so that their care team can see the effect of fatigue on their day-to-day lives. There are many questionnaires that are used to measure fatigue in people with MS. It would be valuable to come to an agreement, based on evidence from research like this study, on which questionnaire is the most appropriate for measuring fatigue in both research and healthcare settings. This study compared a questionnaire called the PROMIS<sup>®</sup> Fatigue (MS) 8a, referred to throughout this summary as the PROMIS<sup>®</sup> MS Fatigue Short Form, with two of the most commonly used questionnaires: the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS). The questionnaires were compared to see which one should be recommended to doctors for measuring fatigue in people with MS.</p><p><strong>What are the key takeaways?: </strong>It was found that while all three questionnaires were good, the PROMIS<sup>®</sup> MS Fatigue Short Form questionnaire was better than the other two questionnaires at showing differences in levels of fatigue between people with MS. The PROMIS<sup>®</sup> MS Fatigue Short Form was also found to be better than the Fatigue Severity Scale (FSS) at showing changes in the person with MS's level of fatigue. The PROMIS<sup>®</sup> MS Fatigue Short Form questionnaire may help people with MS to better communicate challenges with their fatigue to their doctors.</p><p><strong>What was the main conclusion reported by the researchers?: </strong>The study suggests that the PROMIS<sup>®</sup> MS Fatigue Short Form questionnaire is a helpful tool for doctors and people with MS to measure fatigue.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"5-9"},"PeriodicalIF":2.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11244694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Welcome to Volume 14 of Neurodegenerative Disease Management. 欢迎阅读《神经退行性疾病管理》第 14 卷。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2024-02-01 Epub Date: 2024-02-29 DOI: 10.2217/nmt-2023-0045
Afra Paleel
{"title":"Welcome to Volume 14 of <i>Neurodegenerative Disease Management</i>.","authors":"Afra Paleel","doi":"10.2217/nmt-2023-0045","DOIUrl":"10.2217/nmt-2023-0045","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-4"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. 纳比昔莫司治疗多发性硬化症相关痉挛的患者报告获益超过了传统衡量标准。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-02-01 Epub Date: 2024-02-06 DOI: 10.2217/nmt-2023-0040
Michael R Haupts, Ute Essner, Mathias Mäurer

Aim: This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex®) in the real-world setting in Germany. Patients & methods: The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity. Results: The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p < 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0-10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks. Conclusion: Nabiximols is a useful therapeutic option for patients with MS spasticity.

目的:这项为期 12 周的前瞻性、多中心、开放标签、非干预性研究调查了在德国实际环境中添加纳比昔莫司口腔喷雾剂(Sativex®)的有效性和耐受性。患者和方法:主要分析组包括 51 名患有多发性硬化症(MS)痉挛的成年患者(49 名 nabiximols 反应者)。结果从基线到第 12 周,平均总体目标实现量表评分(主要结果测量)增加了 46%(35.2 vs 51.4;P 结论:纳比西莫司是一种有效的治疗药物:纳比昔莫司对多发性硬化痉挛患者是一种有用的治疗选择。
{"title":"Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.","authors":"Michael R Haupts, Ute Essner, Mathias Mäurer","doi":"10.2217/nmt-2023-0040","DOIUrl":"10.2217/nmt-2023-0040","url":null,"abstract":"<p><p><b>Aim:</b> This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex<sup>®</sup>) in the real-world setting in Germany. <b>Patients & methods:</b> The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity. <b>Results:</b> The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p < 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0-10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks. <b>Conclusion:</b> Nabiximols is a useful therapeutic option for patients with MS spasticity.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"11-20"},"PeriodicalIF":2.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139692466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits of self-paced concurrent training on lung function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis. 自定进度的同步训练对多发性硬化症患者肺功能、心肺功能和疲劳感的益处。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1080/17582024.2024.2404385
Sonda Jallouli, Rami Maaloul, Sameh Ghroubi, Rim Kammoun, Mariem Damak, Salma Sakka, Tarak Driss, Giovanni de Marco, Chokri Mhiri, Mohamed Habib Elleuch, Walid Feki, Omar Hammouda

Aim: Studying the effects of self-paced concurrent high-intensity interval training and resistance training (HIIT-RT) on respiratory function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis (PwMS).Methods: Twenty-three PwMS were randomized into a 12-week training group (three times per week) (TG, n = 11) or a control group (CG, n = 12). Lung function (spirometry), aerobic capacity (graded cardiopulmonary-exercise-testing) and perceived fatigue (Fatigue Severity Scale (FSS)) were evaluated pre- and post-intervention.Results: The forced vital capacity (p = 0.036, Hedges'g (g) = 0.93), forced expiratory time (p = 0.045, g = 0.88), peak expiratory flow (p = 0.043, g = 0.89) increased in TG compared with CG. The TG showed an increase in peak aerobic power (p = 0.004, g = 1.34) and peak oxygen uptake (p < 0.001, g = 2.58) compared with CG. There was a decrease in ventilatory equivalent for carbon dioxide (p = 0.02, g = 1.02) and FSS scores (p < 0.001, g = 1.72) in TG comparatively with CG.Conclusion: 12-week self-paced HIIT-RT enhanced lung function as well as aerobic fitness, and alleviated fatigue perception in PwMS.

目的:研究自定步骤同时进行的高强度间歇训练和阻力训练(HIIT-RT)对多发性硬化症患者(PwMS)呼吸功能、心肺功能和疲劳感的影响:23 名多发性硬化症患者被随机分为为期 12 周的训练组(每周三次)(TG,n = 11)或对照组(CG,n = 12)。对干预前后的肺功能(肺活量测定)、有氧运动能力(分级心肺运动测试)和疲劳感(疲劳严重程度量表(FSS))进行评估:结果:与 CG 相比,TG 的用力肺活量(p = 0.036,Hedges'g (g) = 0.93)、用力呼气时间(p = 0.045,g = 0.88)和呼气流量峰值(p = 0.043,g = 0.89)均有所增加。TG 的峰值有氧功率(p = 0.004,g = 1.34)、峰值摄氧量(p p = 0.02,g = 1.02)和 FSS 评分(p 结论:为期 12 周的自定步调 HIIT-RT 可增强 PwMS 的肺功能和有氧体能,并缓解疲劳感。
{"title":"Benefits of self-paced concurrent training on lung function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis.","authors":"Sonda Jallouli, Rami Maaloul, Sameh Ghroubi, Rim Kammoun, Mariem Damak, Salma Sakka, Tarak Driss, Giovanni de Marco, Chokri Mhiri, Mohamed Habib Elleuch, Walid Feki, Omar Hammouda","doi":"10.1080/17582024.2024.2404385","DOIUrl":"10.1080/17582024.2024.2404385","url":null,"abstract":"<p><p><b>Aim:</b> Studying the effects of self-paced concurrent high-intensity interval training and resistance training (HIIT-RT) on respiratory function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis (PwMS).<b>Methods:</b> Twenty-three PwMS were randomized into a 12-week training group (three times per week) (TG, n = 11) or a control group (CG, n = 12). Lung function (spirometry), aerobic capacity (graded cardiopulmonary-exercise-testing) and perceived fatigue (Fatigue Severity Scale (FSS)) were evaluated pre- and post-intervention.<b>Results:</b> The forced vital capacity (<i>p</i> = 0.036, Hedges'g (g) = 0.93), forced expiratory time (<i>p</i> = 0.045, g = 0.88), peak expiratory flow (<i>p</i> = 0.043, g = 0.89) increased in TG compared with CG. The TG showed an increase in peak aerobic power (<i>p</i> = 0.004, g = 1.34) and peak oxygen uptake (<i>p</i> < 0.001, g = 2.58) compared with CG. There was a decrease in ventilatory equivalent for carbon dioxide (<i>p</i> = 0.02, g = 1.02) and FSS scores (<i>p</i> < 0.001, g = 1.72) in TG comparatively with CG.<b>Conclusion:</b> 12-week self-paced HIIT-RT enhanced lung function as well as aerobic fitness, and alleviated fatigue perception in PwMS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"173-187"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options. 难治性抗 NMDAR 脑炎合并多种鼻腔感染:优化治疗方案。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/17582024.2024.2388508
Sachin G Nair, Elezabeth Koshy, Rajender Kandikonda, Sudheeran Kannoth

Nosocomial infections during immunotherapy pose a dilemma in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, where a lack of consensus guidelines for this rare disease marks a significant gap in the existing knowledge. This case reports about an 18-year-old female diagnosed with anti-NMDAR encephalitis who was found to be refractory to first- and second-line treatment. During her hospital stay, the patient encountered nearly six episodes of infection, which delayed the use of next-line intervention. It was observed that switching over to the next line of treatment during infections may produce sub-therapeutic outcomes. Thereby, the case highlights the need for de-escalation and appropriate selection of immunosuppression therapy during nosocomial infections and how monotherapy with the patient-tolerated first-line agent can be appropriate during infection.

在治疗抗 N-甲基-D-天冬氨酸受体(NMDAR)脑炎的过程中,免疫治疗期间的非病原性感染是一个难题,对于这种罕见疾病缺乏共识性指南标志着现有知识的重大空白。本病例报告了一名被诊断患有抗 NMDAR 脑炎的 18 岁女性患者,她对一线和二线治疗均无效。在住院期间,该患者经历了近六次感染发作,延误了下一步治疗。据观察,在感染期间切换到下一治疗线可能会产生亚治疗效果。因此,该病例突出说明了在发生院内感染时,需要降级和适当选择免疫抑制疗法,以及在感染期间如何适当使用患者可耐受的一线药物进行单药治疗。
{"title":"Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options.","authors":"Sachin G Nair, Elezabeth Koshy, Rajender Kandikonda, Sudheeran Kannoth","doi":"10.1080/17582024.2024.2388508","DOIUrl":"10.1080/17582024.2024.2388508","url":null,"abstract":"<p><p>Nosocomial infections during immunotherapy pose a dilemma in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, where a lack of consensus guidelines for this rare disease marks a significant gap in the existing knowledge. This case reports about an 18-year-old female diagnosed with anti-NMDAR encephalitis who was found to be refractory to first- and second-line treatment. During her hospital stay, the patient encountered nearly six episodes of infection, which delayed the use of next-line intervention. It was observed that switching over to the next line of treatment during infections may produce sub-therapeutic outcomes. Thereby, the case highlights the need for de-escalation and appropriate selection of immunosuppression therapy during nosocomial infections and how monotherapy with the patient-tolerated first-line agent can be appropriate during infection.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"63-67"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple system atrophy mimics CASPR2 antibody-associated disease: a case report. 模仿 CASPR2 抗体相关疾病的多系统萎缩:一份病例报告。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-25 DOI: 10.1080/17582024.2024.2388506
Xiaoli Chen, Li Feng, Jing Li, Hong Jiang

Aim: Multiple system atrophy (MSA) and CASPR2 antibody-associated disease bear their own characteristics.Case presentation: A 58-year-old woman presented with a 26 months history of uncoordinated gait and slurred speech. Her serum was positive for anti-CASPR2 antibodies, and MRI revealed atrophy of the brainstem and cerebellum. She underwent three plasma exchanges (PE) and received high doses of corticosteroids without any apparent effect. Her autonomic dysfunction improved after repetitive transcranial magnetic stimulation. Eventually, a diagnosis of MSA-cerebellar phenotype(MSA-C) was made.Conclusion: With increased availability of tools for neuron antibody detection, physicians need to be aware of the possibility that antibodies may accompany other diseases. This report underscores the modern dilemmas caused by available and extensive neuron antibody testing.

目的:多系统萎缩(MSA)和 CASPR2 抗体相关疾病各有特点:一名 58 岁的妇女因步态不协调和言语不清就诊 26 个月。她的血清中抗 CASPR2 抗体呈阳性,核磁共振成像显示脑干和小脑萎缩。她进行了三次血浆置换(PE),并接受了大剂量皮质类固醇治疗,但效果不明显。重复经颅磁刺激后,她的自主神经功能障碍有所改善。最终,她被诊断为MSA-小脑表型(MSA-C):结论:随着神经元抗体检测工具的增多,医生需要意识到抗体可能会伴随其他疾病。本报告强调了神经元抗体检测的可用性和广泛性所带来的现代困境。
{"title":"Multiple system atrophy mimics CASPR2 antibody-associated disease: a case report.","authors":"Xiaoli Chen, Li Feng, Jing Li, Hong Jiang","doi":"10.1080/17582024.2024.2388506","DOIUrl":"10.1080/17582024.2024.2388506","url":null,"abstract":"<p><p><b>Aim:</b> Multiple system atrophy (MSA) and CASPR2 antibody-associated disease bear their own characteristics.<b>Case presentation:</b> A 58-year-old woman presented with a 26 months history of uncoordinated gait and slurred speech. Her serum was positive for anti-CASPR2 antibodies, and MRI revealed atrophy of the brainstem and cerebellum. She underwent three plasma exchanges (PE) and received high doses of corticosteroids without any apparent effect. Her autonomic dysfunction improved after repetitive transcranial magnetic stimulation. Eventually, a diagnosis of MSA-cerebellar phenotype(MSA-C) was made.<b>Conclusion:</b> With increased availability of tools for neuron antibody detection, physicians need to be aware of the possibility that antibodies may accompany other diseases. This report underscores the modern dilemmas caused by available and extensive neuron antibody testing.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"14 3-4","pages":"69-74"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care. 绘制伴有轴突球和色素小体的成人型白质脑病患者和护理伙伴的心路历程图:制定改善护理的框架。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-03 DOI: 10.1080/17582024.2024.2404378
Holly A Rutherford, Beth K Rush, Adam Smith, Erin Sullivan, Clarissa Martinez-Rubio, Ali Toumadj, Roberta La Piana, Cynthia Cassandro

Aim: To identify and raise awareness of healthcare service gaps for individuals with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).Materials & methods: An ALSP patient journey map from symptom onset throughout disease course was developed using existing literature, patient and clinician feedback from a structured workshop and community survey data regarding attitudes toward genetic testing.Results: ALSP diagnosis is frequently delayed due to low awareness of this rare condition and symptom overlap with more common neurological conditions. Multiple factors impact patients' decision-making regarding genetic testing for ALSP, symptom management and participation in research studies.Conclusion: These results highlight the challenges faced by individuals with ALSP and should support program development to improve patient care.

目的:确定并提高对成人型白质脑病伴轴索球形体和色素性胶质细胞(ALSP)患者医疗服务缺口的认识:利用现有文献、患者和临床医生在结构化研讨会上的反馈意见以及有关基因检测态度的社区调查数据,绘制了一张从症状发作到整个病程的ALSP患者旅程图:结果:由于对这种罕见疾病的认识不足以及症状与更常见的神经系统疾病重叠,ALSP的诊断经常被延迟。多种因素影响着患者对 ALSP 基因检测、症状管理和参与研究的决策:这些结果突显了 ALSP 患者所面临的挑战,应支持项目开发以改善患者护理。
{"title":"Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care.","authors":"Holly A Rutherford, Beth K Rush, Adam Smith, Erin Sullivan, Clarissa Martinez-Rubio, Ali Toumadj, Roberta La Piana, Cynthia Cassandro","doi":"10.1080/17582024.2024.2404378","DOIUrl":"10.1080/17582024.2024.2404378","url":null,"abstract":"<p><p><b>Aim:</b> To identify and raise awareness of healthcare service gaps for individuals with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).<b>Materials & methods:</b> An ALSP patient journey map from symptom onset throughout disease course was developed using existing literature, patient and clinician feedback from a structured workshop and community survey data regarding attitudes toward genetic testing.<b>Results:</b> ALSP diagnosis is frequently delayed due to low awareness of this rare condition and symptom overlap with more common neurological conditions. Multiple factors impact patients' decision-making regarding genetic testing for ALSP, symptom management and participation in research studies.<b>Conclusion:</b> These results highlight the challenges faced by individuals with ALSP and should support program development to improve patient care.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"161-172"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and future applications of local field potential-guided programming for Parkinson's disease with the Percept™ rechargeable neurostimulator. 利用 Percept™ 可充电神经刺激器对帕金森病进行局部场电位引导编程的当前和未来应用。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.1080/17582024.2024.2404386
Weerawat Saengphatrachai, Joohi Jimenez-Shahed

Deep brain stimulation (DBS) has been established as an effective neuromodulatory treatment for Parkinson's disease (PD) with motor complications or refractory tremor. Various DBS devices with unique technology platforms are commercially available and deliver continuous, open-loop stimulation. The Percept™ family of neurostimulators use BrainSense™ technology with five key features to sense local field potentials while stimulating, enabling integration of physiologic data into the routine practice of DBS programming. The newly approved Percept™ rechargeable RC implantable pulse generator offers a smaller, thinner design and reduced recharge time with prolonged recharge interval. In this review, we describe the application of local field potential sensing-based programming in PD and highlight the potential future clinical implementation of closed-loop stimulation using the Percept™ RC implantable pulse generator.

脑深部刺激(DBS)已被确定为治疗帕金森病(PD)运动并发症或难治性震颤的有效神经调节疗法。目前市场上有多种具有独特技术平台的 DBS 设备,可提供连续、开环刺激。Percept™ 系列神经刺激器采用 BrainSense™ 技术,具有五大特点,可在刺激的同时感知局部场电位,从而将生理数据整合到 DBS 编程的常规实践中。新批准的 Percept™ 可充电 RC 植入式脉冲发生器设计更小、更薄,充电时间更短,充电间隔更长。在这篇综述中,我们描述了基于局部场电位传感的编程在帕金森病中的应用,并强调了使用 Percept™ RC 植入式脉冲发生器进行闭环刺激的潜在临床应用前景。
{"title":"Current and future applications of local field potential-guided programming for Parkinson's disease with the Percept™ rechargeable neurostimulator.","authors":"Weerawat Saengphatrachai, Joohi Jimenez-Shahed","doi":"10.1080/17582024.2024.2404386","DOIUrl":"10.1080/17582024.2024.2404386","url":null,"abstract":"<p><p>Deep brain stimulation (DBS) has been established as an effective neuromodulatory treatment for Parkinson's disease (PD) with motor complications or refractory tremor. Various DBS devices with unique technology platforms are commercially available and deliver continuous, open-loop stimulation. The Percept™ family of neurostimulators use BrainSense™ technology with five key features to sense local field potentials while stimulating, enabling integration of physiologic data into the routine practice of DBS programming. The newly approved Percept™ rechargeable RC implantable pulse generator offers a smaller, thinner design and reduced recharge time with prolonged recharge interval. In this review, we describe the application of local field potential sensing-based programming in PD and highlight the potential future clinical implementation of closed-loop stimulation using the Percept™ RC implantable pulse generator.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"131-147"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurodegenerative disease management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1